Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword.
Major currently used anticancer therapeutics either directly damage DNA or target and upset basic cell division mechanisms like DNA replication and chromosome segregation. These insults elicit activation of cell cycle checkpoints, safeguard mechanisms that cells implement to correctly complete cell cycle phases, repair damage or eventually commit suicide in case damage is unrepairable. Although cancer cells appear to be advantageously defective in some aspects of checkpoint physiology, recent acquisitions on the biochemical mechanisms of the various checkpoints are offering new therapeutic approaches against cancer. Indeed, chemical manipulation of these mechanisms is providing new therapeutic strategies and tools to increase the killing efficacy of major cancer therapeutics as well as to directly promote cancer cell death. In this review we summarize developing concepts on how targeting cell cycle checkpoints may provide substantial improvement to cancer therapy.
IEOS, CNR, Via S. Pansini 5, 80131, Naples, Italy. r.visconti@ieos.cnr.it.
Roberta
R
Visconti
DMMBM, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy.|CEINGE Biotecnologie Avanzate, Via G. Salvatore 486, 80145, Naples, Italy.
Rosa
R
Della Monica
DMMBM, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy. domenico.grieco@unina.it.|CEINGE Biotecnologie Avanzate, Via G. Salvatore 486, 80145, Naples, Italy. domenico.grieco@unina.it.
Domenico
D
Grieco
Cancer drug; Cell cycle checkpoint; Chk1; DNA damage; Fcp1; Mitosis; Spindle assembly checkpoint; Taxane; Vinca alkaloids; Wee1
Cell. 1994 Nov 18;79(4):573-82
7954824
Clin Cancer Res. 2006 Dec 1;12(23):7079-85
17145831
J Biol Chem. 2003 Jun 13;278(24):21767-73
12676925
Mol Cancer Ther. 2002 Oct;1(12):1067-78
12481430
J Exp Clin Cancer Res. 2015 Feb 05;34:13
25652119
Curr Cancer Drug Targets. 2011 Mar;11(3):380-92
21247380
J Natl Cancer Inst Monogr. 1993;(15):55-61
7912530
Int J Oncol. 2012 Jan;40(1):194-202
21894433
Cell Death Differ. 2015 Sep;22(9):1551-60
25744022
EMBO J. 1997 Feb 3;16(3):545-54
9034337
Science. 1999 Oct 29;286(5441):971-4
10542155
J Exp Clin Cancer Res. 2011 Oct 05;30:93
21970649
Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27
18594563
EMBO J. 2010 Jul 21;29(14):2407-20
20526282
Mol Cancer Ther. 2013 Feb;12(2):141-50
23270927
Curr Opin Drug Discov Devel. 2005 Jul;8(4):431-6
16022179
Cell Cycle. 2007 Oct 1;6(19):2348-54
17700074
Mol Cancer Ther. 2009 Nov;8(11):2992-3000
19887545
Elife. 2015 Dec 14;4:
26653855
Curr Opin Cell Biol. 2013 Dec;25(6):780-5
23890995
Curr Med Chem Anticancer Agents. 2005 Jan;5(1):65-71
15720262
J Exp Clin Cancer Res. 2009 Sep 23;28:130
19775446
Cell Cycle. 2013 Oct 1;12(19):3159-64
24013427
Invest New Drugs. 2012 Apr;30(2):741-8
20967484
Nature. 2004 Nov 18;432(7015):316-23
15549093
Cancer Discov. 2012 Jun;2(6):524-39
22628408
Science. 1998 Sep 11;281(5383):1677-9
9733515
Science. 1997 Sep 5;277(5331):1497-501
9278511
Eur J Med Chem. 2013 Apr;62:614-31
23434636
Br J Cancer. 2011 Jul 26;105(3):372-81
21730979
Mol Cancer Ther. 2009 Jan;8(1):45-54
19139112
Science. 1998 Sep 11;281(5383):1674-7
9733514
Drug Discov Today. 2012 Mar;17(5-6):194-202
22192883
Mol Cell Biol. 2012 Oct;32(20):4226-36
22907750
Nat Rev Cancer. 2012 Dec;12(12):801-17
23175119
Trends Biochem Sci. 2011 Sep;36(9):478-84
21741842
Science. 2000 May 26;288(5470):1425-9
10827953
Curr Opin Drug Discov Devel. 2009 Mar;12(2):240-5
19333869
Clin Cancer Res. 2012 Oct 15;18(20):5650-61
22929806
Curr Biol. 2006 Jun 20;16(12):1194-200
16782009
J Clin Oncol. 2015 Mar 20;33(9):1075-7
25691674
Curr Opin Cell Biol. 2007 Apr;19(2):238-45
17303408
Mol Cancer Ther. 2012 Jan;11(1):174-82
22084170
J Cell Sci. 2009 Aug 1;122(Pt 15):2579-85
19625502
Mol Cancer Ther. 2008 Aug;7(8):2394-404
18723486
Cell Death Dis. 2012 Oct 18;3:e411
23076219
Nature. 2009 Oct 22;461(7267):1071-8
19847258
Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49
24448638
Nat Rev Mol Cell Biol. 2013 Apr;14(4):197-210
23847781
J Exp Clin Cancer Res. 1997 Sep;16(3):237-42
9387895
Cell Cycle. 2007 Jan 1;6(1):104-10
17245119
Science. 1998 Dec 4;282(5395):1893-7
9836640
Dev Cell. 2004 Nov;7(5):637-51
15525526
J Biol Chem. 1997 Aug 29;272(35):22300-6
9268380
Clin Cancer Res. 2005 Jun 15;11(12):4444-50
15958629
Oncotarget. 2015 Feb 20;6(5):3394-408
25428911
Cancer Lett. 2014 Feb 28;343(2):232-8
24099917
Clin Cancer Res. 1996 May;2(5):791-7
9816232
Cell. 1997 Oct 31;91(3):325-34
9363941
Nature. 1993 Dec 16;366(6456):707-10
8259216
Cell. 1993 Nov 19;75(4):817-25
8242752
Cancer Biol Ther. 2010 Apr 1;9(7):514-22
20107315
Curr Opin Pharmacol. 2013 Aug;13(4):529-35
23597425
J Clin Oncol. 2015 Oct 20;33(30):3409-15
25964244
Cancer Res. 2004 Dec 15;64(24):9035-40
15604269
Mol Cell. 2007 Apr 27;26(2):301-10
17466630
Nature. 2001 Apr 12;410(6830):842-7
11298456
Cell Signal. 2013 May;25(5):1086-95
23416462
Genes Dev. 2003 Oct 15;17(20):2520-5
14561775
J Cell Biol. 2001 Sep 3;154(5):925-36
11535616
Mol Cancer Ther. 2013 Aug;12(8):1442-52
23699655
Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92
21527953
EMBO J. 1995 Oct 16;14(20):4994-5005
7588628
Breast Cancer Res Treat. 2013 Jan;137(2):483-92
23242585
Science. 1992 Sep 25;257(5078):1955-7
1384126
Cell. 1993 Nov 19;75(4):805-16
8242751
J Clin Oncol. 2015 Mar 20;33(9):1060-6
25605849
Clin Cancer Res. 2011 May 1;17(9):2799-806
21389100
Cell Biol Int. 2014 Jun;38(6):737-46
24677263
Nat Commun. 2012 Jun 12;3:894
22692537
Crit Rev Biochem Mol Biol. 2012 May-Jun;47(3):222-35
22324461
Clin Cancer Res. 2011 Sep 1;17(17):5638-48
21799033
Clin Cancer Res. 2012 Dec 15;18(24):6723-31
23092873
Nat Rev Cancer. 2002 Aug;2(8):594-604
12154352
Science. 1996 Dec 6;274(5293):1672-7
8939849
Nat Rev Cancer. 2010 Dec;10(12):825-41
21102634
J Exp Clin Cancer Res. 2014 Jan 29;33:13
24476310
Nat Rev Mol Cell Biol. 2001 Jan;2(1):21-32
11413462
Nat Rev Mol Cell Biol. 2007 May;8(5):379-93
17426725
Cell Cycle. 2013 Jan 1;12(1):17-9
23255109
Mol Cancer Ther. 2012 Feb;11(2):427-38
22203733
Invest New Drugs. 2016 Oct;34(5):625-35
27350064